Tetracosactide - Novartis

Drug Profile

Tetracosactide - Novartis

Alternative Names: Corticotropin tetracosapeptide; Cosyntropin injection; Cosyntropin zinc hydroxide injection; MNK-1411; Synacthen; Synacthen Depot; Tetracosactide hexa-acetate salt - Novartis

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Alliance Pharmaceuticals Limited; Defiante Farmaceutica; Leadiant Biosciences; Mallinckrodt plc; Novartis; Swedish Orphan Biovitrum
  • Class Anti-inflammatories; Corticosteroids; Immunotherapies; Melanocortins; Peptides
  • Mechanism of Action Melanocortin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adrenal insufficiency; Autoimmune disorders; Infantile spasms; Inflammation; Multiple sclerosis
  • Phase I Duchenne muscular dystrophy

Most Recent Events

  • 14 Jul 2017 Tetracosactide licensed to West Therapeutic Development in USA for the treatment of Infantile spasms and Nephrotic syndrome
  • 12 Jul 2017 Tetracosactide receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 12 Jul 2017 Mallinckrodt plans a phase II trial for Duchenne muscular dystrophy in late 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top